Last reviewed · How we verify
Phenarol (CHLORMEZANONE)
Phenarol, also known as chlormezanone, is a small molecule drug in the chlormezanone class. It was originally developed and is currently owned by a company, but the exact details are not specified. Phenarol is FDA-approved for the treatment of anxiety and was approved in 1960. It has a high bioavailability of 99% but lacks generic manufacturers due to its off-patent status. As an off-patent medication, Phenarol is no longer protected by active patents.
At a glance
| Generic name | CHLORMEZANONE |
|---|---|
| Drug class | chlormezanone |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1960 |
Approved indications
- Anxiety
Common side effects
Key clinical trials
- Antipsychotics and Risk of Hyperglycemic Emergencies
- Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |